NDC codes

FDA NDC Directory
Product NDC (as listed)70121-1568Labeler and product segments. Claims need a package NDC.
Product NDC at billing width70121-1568Add the package segment from the table below.
Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC11-digit (billing)PackageCopy
70121-1568-1701211568011 SYRINGE in 1 BOX (70121-1568-1) / .5 mL in 1 SYRINGEMarketed from Feb 25, 2022
70121-1568-77012115680710 SYRINGE in 1 BOX (70121-1568-7) / .5 mL in 1 SYRINGEMarketed from Feb 25, 2022

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary)
Releuko
Generic name (nonproprietary)
filgrastim
Active ingredients
Filgrastim — 300 ug/.5mL
Dosage form
Injection, Solution
Route
Intravenous, Subcutaneous
Product type
Prescription drug
Marketing category
BLA — Biologics License ApplicationApplication BLA 761082
Marketing start
Listing expires
Other FDA classes
Granulocyte Colony-Stimulating Factor (Chemical structure)Increased Myeloid Cell Production (Physiologic effect)
Identifiers
Product ID 70121-1568_7dd755fd-d4fe-431a-97a2-1ded5cf1a24bSPL ID 7dd755fd-d4fe-431a-97a2-1ded5cf1a24bSPL set ID 74e1ec6e-1630-4654-895c-2bd355f939e7RxCUI 2595944, 2595950, 2595953, 2595957, 2595959, 2595960, 2595961, 2595962UNII PVI5M0M1GWUPC 0370121156970, 0370121156819, 0370121157014, 0370121156871, 0370121157175, 0370121157076
Pharmacologic class
Leukocyte Growth Factor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N470121156801 followed by a unit qualifier and the quantity

Package 70121-1568-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective .

Indications (excerpt from the label)

RELEUKO is a leukocyte growth factor indicated to: Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti- cancer drugs associated with a significant incidence of severe neutropenia with fever. ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). ( 1.2 ) Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 761082

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761082
ProductStrengthForm · routeLabelerProduct NDC
ReleukofilgrastimFilgrastim 300 ug/mLInjection, SolutionIntravenous, SubcutaneousAmneal Pharmaceuticals LLC70121-1569
ReleukofilgrastimFilgrastim 480 ug/.8mLInjection, SolutionIntravenous, SubcutaneousAmneal Pharmaceuticals LLC70121-1570
ReleukofilgrastimFilgrastim 480 ug/1.6mLInjection, SolutionIntravenous, SubcutaneousAmneal Pharmaceuticals LLC70121-1571

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free Med-Code account to keep looking up NDCs, J-codes and drugs.

Create a free accountLog in
Releuko (filgrastim) NDC 70121-1568 | Med-Code